Position Statement of the Argentine Federation of Cardiology, Exercise Cardiology Committee on sports activity in hypertrophic cardiomyopathy
DOI:
https://doi.org/10.63600/ye1snx38Keywords:
Hypertrophic cardiomyopathy, Exercise, Competitive sport, Sudden death, Shared decision makingAbstract
Historically, individuals with hypertrophic cardiomyopathy (HCM) have been excluded from vigorous exercise and competitive sports due to the risk of sudden cardiac death (SCD), based on retrospective studies. Recent evidence has challenged this paradigm, demonstrating improvements in functional capacity, quality of life, cardiovascular and psychological health when competitive sports are included in low-risk individuals. For those who do not meet these criteria, the evidence is more limited. However, participation in competitive sports can still be considered on an individual basis.
A contemporary approach to HCM should be based on individualized, goal-oriented exercise prescription, multidisciplinary intervention, and shared decision-making.
In this review, we critically appraise the evidence on vigorous exercise and competitive sports and explore how new data are reshaping clinical practice and international guidelines, laying the groundwork for a new paradigm in the field.
References
Bibliografía
1. Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(23):2324–405.
2. Zampieri M, Saberi S, D'Ascenzi F, Papadakis M, Pelliccia A, Olivotto I. Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. Eur Heart J. 2026;47(8):902–15.
3. Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM, et al. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. Circulation. 2023;148(2):174–95.
4. Kim JH, Baggish AL, Levine BD, Ackerman MJ, Day SM, Dineen EH, et al. Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2025;151(11):e716–e61.
5. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–626.
6. Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Heliö T, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(19):1448–58.
7. Finocchiaro G, Sheikh N, Biagini E, Papadakis M, Maurizi N, Sinagra G, et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020;17(1):142–51.
8. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761–96.
9. Salinas-Arce J, Gonzales-Luna AC, Cabrera-Saldaña M, Mendoza-Novoa P, Alca-Clares R, Solorzano-Altamirano P, et al. [Arrhythmias and Sudden Death Risk in Hypertrophic Cardiomyopathy]. Arch Peru Cardiol Cir Cardiovasc. 2020;1(2):94–104.
10. Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(11):1374–86.
11. Sharma S, Elliott P, Whyte G, Jones S, Mahon N, Whipp B, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86(2):162–8.
12. Drinko JK, Nash PJ, Lever HM, Asher CR. Safety of stress testing in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(11):1443–4, a12.
13. Sharma S, Firoozi S, McKenna WJ. Value of exercise testing in assessing clinical state and prognosis in hypertrophic cardiomyopathy. Cardiol Rev. 2001;9(2):70–6.
14. Willixhofer R, Mapelli M, Baracchini N, Campana N, Capovilla TM, Nava A, et al. Cardiopulmonary exercise testing in hypertrophic cardiomyopathy: the role of reduced O2 pulse and chronotropic incompetence in myocardial adaptation. Eur J Prev Cardiol. 2025.
15. Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000;36(3):864–70.
16. Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A, et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022;35(6):533–69.
17. Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005;91(7):920–5.
18. Haland TF, Almaas VM, Hasselberg NE, Saberniak J, Leren IS, Hopp E, et al. Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2016;17(6):613–21.
19. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17–96.
20. Wolff S, Venegas P, Franco C, Peidro R. Imágenes Cardíacas en Cardiología del Ejercicio: Distribuna Editorial Médica; 2025.
21. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387–98.
22. Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol. 2018;107(1):30–41.
23. Lampert R, Chung EH, Ackerman MJ, Arroyo AR, Darden D, Deo R, et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. Heart Rhythm. 2024;21(10):e151–e252.
24. Leggit JC, Whitaker D. Diagnosis and Management of Hypertrophic Cardiomyopathy: Updated Guidelines From the ACC/AHA. Am Fam Physician. 2022;105(2):207–9.
25. Miller EM, Brown E, Christian S, Kelly MA, Knight LM, Saberi S, et al. Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors. J Genet Couns. 2025;34(3):e1993.
26. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NA, 3rd, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e273–80.
